Effect of N-Acetylcysteine on Neutrophil Lymphocyte Ratio And Length of Stay In COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
This research is a study that compares the administration of N-acetylcysteine at various doses with the outcomes of COVID-19 patients, namely the neutrophil-to-lymphocyte ratio and length of stay.

Detailed Description
-----------------
This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into four groups. The control group K0 received standard therapy without NAC, while the treatment group K1 received NAC injections of 1200mg/day, K2 NAC tablets 3x400mg/day, and K3 NAC tablets 3x200mg/day. Different tests using Way ANOVA and LSD or Kruskal-Wallis and Mann-Whitney.

Official Title
-----------------
Effect of N-Acetylcysteine on Neutrophil Lymphocyte Ratio And Length of Stay In COVID-19 Patients

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Drug: N-acetyl cysteine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: moderate or severe grade confirmed COVID-19 (patients with symptoms and radiological examination showing pneumonia with or without signs of severe pneumonia: SpO2<90%, respiratory rate>30x/min, and severe respiratory distress) who were admitted to UNS Hospital and age 18-60 years old Exclusion Criteria: patients who died during the treatment period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Interventional Model Description: This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into four groups. The control group K0 received standard therapy without NAC, while the treatment group, K1, received NAC injections of 1200mg/day, K2 NAC tablets 3x400mg/day, and K3 NAC tablets 3x200mg/day. Different tests using Way ANOVA and LSD or Kruskal-Wallis and Mann-Whitney.
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: N-acetylcysteine injection 1200 mg<br>N-acetylcysteine injection 1200 mg per day | Drug: N-acetyl cysteine<br>* N-acetyl cysteine dosage 600 mg and 1200 mg<br>|
| Experimental: N-acetylcysteine pill 1200 mg<br>N-acetylcysteine pill 1200 mg orally per day | Drug: N-acetyl cysteine<br>* N-acetyl cysteine dosage 600 mg and 1200 mg<br>|
| Experimental: N-acetylcysteine pills 600 mg per day<br>N-acetylcysteine pills 600 mg per day orally | Drug: N-acetyl cysteine<br>* N-acetyl cysteine dosage 600 mg and 1200 mg<br>|
| Placebo Comparator: placebo<br>Capsule with shape and appearance similar to N-acetylcysteine | Drug: N-acetyl cysteine<br>* N-acetyl cysteine dosage 600 mg and 1200 mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neutrophil to lymphocyte ratio | Neutrophil to lymphocyte ratio | Change of Neutrophil to lymphocyte ratio at 7 day | 
| Length of stay | Length of stay | From date of randomization until the date of return from hospital |